SARS-CoV-2(COVID-19)
暂无分享,去创建一个
[1] Y. Hu,et al. [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.
[2] N. Osman. Faculty Opinions recommendation of 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[3] Xiliang Wang,et al. COVID-19: a new challenge for human beings , 2020, Cellular & Molecular Immunology.
[4] T. Lupia,et al. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge , 2020, Journal of Global Antimicrobial Resistance.
[5] W. Ko,et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges , 2020, International Journal of Antimicrobial Agents.
[6] S. Meo,et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. , 2020, European review for medical and pharmacological sciences.
[7] S. Lindstrom,et al. First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.
[8] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[9] Weier Wang,et al. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China , 2020, Journal of medical virology.
[10] Hongzhou Lu,et al. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle , 2020, Journal of medical virology.